Drug intelligence / Profile preview

Spur Therapeutics cardioprotective gene therapy

Development stage: Preclinical
Lead developer: Spur Therapeutics
Modality: Gene Therapies

Overview

Spur Therapeutics (formerly Freeline Therapeutics) is developing an unnamed, research-stage gene therapy program for the treatment of severe chronic heart failure. The approach involves the delivery of genes encoding a suite of cardioprotective proteins designed to improve cardiac function and arrest the progression of heart failure. This program marks the company's strategic expansion from rare monogenic diseases into more common, prevalent chronic conditions. As of 2024, a specific lead candidate has not been publicly named, and the program remains in the research phase.

Other names: Unnamed cardioprotective gene therapy programFreeline Therapeutics heart failure program

Beyond the preview

Go deeper on Spur Therapeutics cardioprotective gene therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spur Therapeutics cardioprotective gene therapy.

Explore the full profile